Cargando…

Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC

The prognosis of advanced non-small cell lung cancer (NSCLC) is poor; therefore, identifying novel treatment strategies for patients with NSCLC is important. The present study aimed to investigate the efficacy of apatinib plus docetaxel vs. docetaxel alone, as well as their effects on regulating aut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Rong, Li, Tao, Hui, Kaiyuan, Chen, Zi, Wang, Nan, Wu, Xingping, Ge, Linyang, Zhou, Linfu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533512/ https://www.ncbi.nlm.nih.gov/pubmed/32901884 http://dx.doi.org/10.3892/mmr.2020.11492

Ejemplares similares

Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report
por: Zhao, Yuanyang, et al.
Publicado: (2021)

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
por: Zhou, Ling, et al.
Publicado: (2023)

Significant efficacy and well safety of apatinib combined with radiotherapy in NSCLC: Case report
por: Zhao, Chunbo, et al.
Publicado: (2017)

Molecular Mechanisms of Chemoresistance Induced by Cisplatin in NSCLC Cancer Therapy
por: Kryczka, Jolanta, et al.
Publicado: (2021)

Apatinib with EGFR-TKIs in advanced wild gene-type NSCLC: A case report
por: Wu, Yuan-Peng, et al.
Publicado: (2019)

Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study
por: Tang, Jing, et al.
Publicado: (2019)

TIMP-1-Mediated Chemoresistance via Induction of IL-6 in NSCLC
por: Xiao, Wei, et al.
Publicado: (2019)

TIMP-1 Dependent Modulation of Metabolic Profiles Impacts Chemoresistance in NSCLC
por: Xiao, Wei, et al.
Publicado: (2022)

Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
por: Yuan, Shumin, et al.
Publicado: (2022)

Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR
por: Fang, Shencun, et al.
Publicado: (2017)

Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study
por: Liang, Jianmiao, et al.
Publicado: (2020)

Association Between PDL1 Genetic Variation and Efficacy of Apatinib Monotherapy in Patients with Previously Treated Advanced NSCLC: A Real-World Retrospective Study
por: Hu, Wenxia, et al.
Publicado: (2021)

Specific inhibitor of Notch-3 enhances the sensitivity of NSCLC cells to gemcitabine
por: Hu, Bi-Dan, et al.
Publicado: (2018)

Correction to: Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
Publicado: (2022)

SMYD3 confers cisplatin chemoresistance of NSCLC cells in an ANKHD1-dependent manner
por: Lv, Hong-Wei, et al.
Publicado: (2021)

Long-Term Recurrence of Completely Resected NSCLC
por: Masago, Katsuhiro, et al.
Publicado: (2020)

YBX1 mediates autophagy by targeting p110β and decreasing the sensitivity to cisplatin in NSCLC
por: Cui, Yanwei, et al.
Publicado: (2020)

Therapeutic Sequencing in ALK(+) NSCLC
por: Elsayed, Mei, et al.
Publicado: (2021)

CIAPIN1 Targeted NHE1 and ERK1/2 to Suppress NSCLC Cells' Metastasis and Predicted Good Prognosis in NSCLC Patients Receiving Pulmonectomy
por: Wang, Jian, et al.
Publicado: (2019)

Inhibition of JNK-mediated autophagy enhances NSCLC cell sensitivity to mTORC1/2 inhibitors
por: Jin, Hyeon-Ok, et al.
Publicado: (2016)

Combination of Cordycepin and Apatinib Synergistically Inhibits NSCLC Cells by Down-Regulating VEGF/PI3K/Akt Signaling Pathway
por: Liao, Xiaozhong, et al.
Publicado: (2020)

In vitro and in vivo analyses on anti-NSCLC activity of apatinib: rediscovery of a new drug target V600E mutation
por: Chen, Jiani, et al.
Publicado: (2023)

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations
por: Yang, Yudie, et al.
Publicado: (2022)

SKIL facilitates tumorigenesis and immune escape of NSCLC via upregulating TAZ/autophagy axis
por: Ma, Fang, et al.
Publicado: (2020)

Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series
por: Zhang, Honghong, et al.
Publicado: (2017)

Combination of rapamycin and SAHA enhanced radiosensitization by inducing autophagy and acetylation in NSCLC
por: Wang, Yong, et al.
Publicado: (2021)

AS-IV enhances the antitumor effects of propofol in NSCLC cells by inhibiting autophagy
por: Liu, Jintao, et al.
Publicado: (2023)

Survival Outcomes of Salvage Therapy for Local and Regionally Recurrent NSCLC
por: Moore, Sara, et al.
Publicado: (2020)

Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway
por: Hou, Xiaoying, et al.
Publicado: (2018)

Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study
por: Jiang, Qian, et al.
Publicado: (2019)

Continuous Low-Dose Apatinib Combined With WBRT Significantly Reduces Peritumoral Edema and Enhances the Efficacy of Symptomatic Multiple Brain Metastases in NSCLC
por: Ren, Yue, et al.
Publicado: (2021)

A novel defined pyroptosis-related gene signature predicts prognosis and correlates with the tumour immune microenvironment in lung adenocarcinoma
por: Chen, Zi, et al.
Publicado: (2023)

Focus on Nivolumab in NSCLC
por: Cortinovis, Diego L., et al.
Publicado: (2016)

Angiogenesis Inhibitors in NSCLC
por: Manzo, Anna, et al.
Publicado: (2017)

Immunotherapeutic Advances for NSCLC
por: Massafra, Marco, et al.
Publicado: (2021)

Targeting AXL in NSCLC
por: Zaman, Aubhishek, et al.
Publicado: (2021)

Precision Surgery in NSCLC
por: Cannone, Giorgio, et al.
Publicado: (2023)

PHF23 promotes NSCLC proliferation, metastasis, and chemoresistance via stabilization of ACTN4 and activation of the ERK pathway
por: Cheng, Ming, et al.
Publicado: (2023)

Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment
por: Wang, Jing, et al.
Publicado: (2018)

An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study
por: Li, Ning, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r8qco9ndjv2j0erc5t8n05frgp